Indian Journal of Respiratory Care

IJRC Email      Register      Login

VOLUME 13 , ISSUE 1 ( January-March, 2024 ) > List of Articles


A Literature Review of Most Common Symptoms in Respiratory Therapist's Practice: How to Manage Dyspnea in Interstitial Lung Disease

Mohankumar Thekkinkattil

Keywords : Corticosteroids, Dyspnea, Interstitial, Lung disease

Citation Information : Thekkinkattil M. A Literature Review of Most Common Symptoms in Respiratory Therapist's Practice: How to Manage Dyspnea in Interstitial Lung Disease. Indian J Respir Care 2024; 13 (1):50-53.

DOI: 10.5005/jp-journals-11010-1092

License: CC BY-NC 4.0

Published Online: 06-04-2024

Copyright Statement:  Copyright © 2024; The Author(s).


Dyspnea is a distressing symptom prevalent in interstitial lung disease (ILD) patients, significantly affecting their quality of life. Understanding the multifaceted nature of dyspnea in ILD is crucial for comprehensive patient care. This article supplies an in-depth exploration of dyspnea in ILD, covering its causes, pathophysiological mechanisms, diagnostic strategies, and treatment approaches. The causes of dyspnea in ILD encompass a spectrum of factors including restrictive lung function, alveolar damage, impaired gas exchange, pulmonary vascular involvement, inflammation, and scarring. These factors collectively contribute to the challenging symptomatology experienced by ILD patients. Pathophysiologically, dyspnea in ILD stems from altered lung mechanics, compromised gas exchange due to fibrotic changes, pulmonary vascular remodeling, and intricate neural pathways involved in dyspnea perception. Diagnosis of dyspnea in ILD necessitates a comprehensive approach involving clinical history, physical examinations, pulmonary function tests (PFTs), imaging studies, biomarkers, and functional assessments like cardiopulmonary exercise testing (CPET). Treatment strategies encompass a multidisciplinary approach, integrating pharmacological interventions such as corticosteroids, immunosuppressants, and antifibrotic agents, alongside pulmonary rehabilitation, oxygen therapy, and in severe cases, lung transplantation. This article highlights recent research developments, clinical trials, and advancements in understanding and managing dyspnea in ILD patients. Continual exploration and personalized approaches are imperative to alleviate the burden of dyspnea and enhance the lives of those affected by ILD.

PDF Share
  1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788–824. DOI: 10.1164/rccm.2009-040GL
  2. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188(6):733–748. DOI: 10.1164/rccm.201308-1483ST
  3. Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168(5):538–542. DOI: 10.1164/rccm.200211-1311OC
  4. Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 2010;36(5):1067–1072. DOI: 10.1183/09031936.00079310
  5. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104(2):296–304. DOI: 10.1016/j.rmed.2009.09.006
  6. Swigris JJ, Kuschner WG, Jacobs SS, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005;60(7):588–594. DOI: 10.1136/thx.2004.035220
  7. Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology 2008;13(3):394–399. DOI: 10.1111/j.1440-1843.2007.01208.x
  8. Brown KK, Martinez FJ. Clinical aspects of idiopathic pulmonary fibrosis. In: Fishman's pulmonary diseases and disorders. 5th ed. McGraw-Hill; 2015.
  9. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet 2017;389(10082):1941–1952. DOI: 10.1016/S0140-6736(17)30866-8
  10. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378(9807):1949–1961. DOI: 10.1016/S0140-6736(11)60052-4
  11. Nathan SD, Shlobin OA, Barnett SD, et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008;102(9):1305–1310. DOI: 10.1016/j.rmed.2008.04.012
  12. Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc 2006;3(4):285–292. DOI: 10.1513/pats.200601-005TK
  13. Parshall MB, Schwartzstein RM, Adams L, et al. An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea. Am J Respir Crit Care Med 2012;185(4):435–452. DOI: 10.1164/rccm.201111-2042ST
  14. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018;6(2):138–153. DOI: 10.1016/S2213-2600(17)30433-2
  15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166(1):111–117. DOI: 10.1164/ajrccm.166.1.at1102
  16. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. DOI: 10.1164/rccm.201807-1255ST
  17. Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 2014;35(2):181–200. DOI: 10.1055/s-0034-1371537
  18. Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44(6):1428–1446. DOI: 10.1183/09031936.00150314
  19. Raghu G, Selman M. Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions. Am J Respir Crit Care Med 2015;191(3):252–254. DOI: 10.1164/rccm.201412-2143ED
  20. Holland AE, Hill CJ, Conron M, et al. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax 2008;63(6):549–554. DOI: 10.1136/thx.2007.081893
  21. Visca D, Mori L, Tsipouri V, et al. Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med 2018;6(10):759–770. DOI: 10.1016/S2213-2600(18)30289-3
  22. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant 2019;38(10):1042–1055. DOI: 10.1016/j.healun.2019.08.001
  23. Lindell KO, Olshansky E, Song MK, et al. Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. Heart Lung 2010;39(4):304–313. DOI: 10.1016/j.hrtlng.2009.08.005
  24. Smith SM, Wulff J, Saiki C, et al. Neurogenic inflammation in the context of interstitial lung disease: implications for peripheral nerves and vascular dysfunction. Respir Res 2021;22(1):182. DOI: 10.1186/s12931-021-01834-6
  25. Johnson NJ, Cottrell C, Stanton M, et al. Sensory nerve remodeling in hypoxia-induced pulmonary hypertension and fibrosis. Am J Respir Cell Mol Biol 2020;63(6):806–816. DOI: 10.1165/rcmb.2020-0028OC
  26. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381(18):1718–1727. DOI: 10.1056/NEJMoa1908681
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.